Overview

Testosterone and Alendronate in Hypogonadal Men

Status:
Suspended
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This study will investigate the hypothesis that the combination of testosterone replacement and alendronate will improve bone density and parameters of bone quality more than either medication alone in older men with low testosterone levels and low bone density.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Endo Pharmaceuticals
Merck Sharp & Dohme Corp.
Treatments:
Alendronate
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate